Drug-drug interaction between warfarin and statins: A Danish cohort study

Anna E. Engell1 | Andreas L.O. Svendsen2 | Bent S. Lind1 | Christen L. Andersen3,4 | John S. Andersen5 | Tora G. Willadsen5 | Frederik Persson6 | Anton Pottegård7

1Department of Clinical Biochemistry, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark
2Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark
3Copenhagen Primary Care Laboratory (CopLab) Database, Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Denmark
4Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
5Research Unit for General Practice, Department of Public Health, Copenhagen University, Copenhagen, Denmark
6Steno Diabetes Center Copenhagen, Gentofte, Denmark
7Clinical Pharmacology and Pharmacy, Department of Public health, University of Southern Denmark, Odense, Denmark

Correspondence
Anna E. Engell, MD, Department of Clinical Biochemistry, University Hospital Hvidovre, Kettegaard Allé 30 2650, Hvidovre, Denmark. Email: anna.elise.engell@regionh.dk

Initiation of statin treatment is suggested to increase the international normalised ratio (INR) among warfarin users. However, available data is limited and conflicting. We conducted a register-based cohort study to evaluate the drug-drug interaction between warfarin and statins.

By linking data on INR measurements and filled prescriptions, we identified warfarin users 2000-2015 initiating simvastatin (n = 1363), atorvastatin (n = 165) or rosvustatin (n = 23). Simvastatin initiation led to an increase in mean INR from 2.40 to 2.71, with INRs peaking after 4 weeks, corresponding to a mean change of 0.32 (95%CI 0.25-0.38). High-dose and low-dose simvastatin led to comparable changes (mean change 0.33 vs 0.29). Initiation of atorvastatin and rosvustatin lead to INR increases of 0.27 (95%CI 0.12-0.42) and 0.30 (95%CI -0.09-0.69).

In conclusion, initiation of simvastatin, atorvastatin or rosvustatin among warfarin users led to a minor increase in INR. The magnitude of this change is for most patients likely of limited clinical relevance.

KEYWORDS
anticoagulants and warfarin, drug interactions, statins

1 | INTRODUCTION

The vitamin K antagonist warfarin is used in the treatment and prevention of thromboembolic events.1–3 Due to its narrow therapeutic index, use of warfarin requires close monitoring of the international normalised ratio (INR). Warfarin is metabolised by the cytochrome P450 (CYP) liver enzymes, especially CYP2C9,4 which makes it highly susceptible to drug-drug interactions (DDIs).3,4 Statins are also metabolized by some of the same CYP enzymes and transporters dependent of statin type, eg, simvastatin is metabolised by CYP3A4, 2C8, 2D6 and MRP2, atorvastatin by CYP3A4, 2C8 and OATP1B1, and rosvustatin by CYP2C9, 2C19 and OATP1B1.5

Due to several overlaps in indications of use, coadministration of warfarin and statins is common.6,7 A limited number of generally conflicting studies have reported both that statin initiation leads to moderate INR increases8–11 and that small INR changes are of limited clinical relevance.12,13 Despite limited evidence of a clinically relevant interaction between warfarin and statins, commonly used online DDI guidelines consistently advise clinicians to increase the frequency of INR monitoring and if necessary adjust the warfarin dose when initiating statin treatment.14–16 This results in additional consultations and blood testing, burdening both the patient and the healthcare system.

To provide additional data on this potential DDI between statins and warfarin, we conducted a large register-based study and
examined the INR changes in warfarin users following exposure to simvastatin, atorvastatin and rosuvastatin.

2 | METHODS

2.1 | Base cohort and data sources

A base cohort was established by linking different Danish health registries. The base cohort comprised all patients registered with at least one INR measurement in the Copenhagen Primary Care Laboratory (CopLab) database. The database includes laboratory test results from primary healthcare patients in the Copenhagen area of Denmark from 2000 to 2015.\textsuperscript{7,18} During this period the primary healthcare doctors in the Copenhagen area were served by the Elective Laboratory of the Capital Region (ELCR). ELCR covers approximately 1.2 million inhabitants and provides a wide range of biochemical, physiological and cardiac tests. The CopLab database does not include INR point-of-care testing (POCT) results from general practice. The ELCR was accredited for International Organization for Standardization (ISO) standards ISO17025 and ISO15189. Appendix A provides a detailed description of the INR assay.

For the cohort identified via CopLab, we retrieved data about drug use from the Danish National Prescription Registry\textsuperscript{19} as well as hospital diagnoses from the Danish National Patient Registry (NPR).\textsuperscript{20} Data linkage was done using the unique Danish Civil Registration Number assigned to all Danish residents.\textsuperscript{21}

2.2 | Study population

From the base cohort (see above) we restricted the dataset to patients with at least two INR measurements, at least one recorded vitamin K antagonist (VKA) dispensing and at least one statin dispensing. Within this cohort we identified all incident prescriptions for simvastatin, atorvastatin and rosuvastatin, defined as a prescription with no preceding prescription for a statin within the last 2 years. If one individual had two such incident prescriptions for the same statin, only the first was included. We further restricted to those with at least one INR measurement 8 weeks before statin initiation, as well as at least one INR measurement within 12 weeks after statin initiation. Finally, we excluded those with no VKA prescription within 180 days before statin initiation and those aged <18 years at the time of statin initiation.

2.3 | Main analysis

The INR results were measured from 8 weeks before statin initiation to 12 weeks after statin initiation. We graphically depicted the changes in INR values by mapping median, interquartile, and 10th and 90th percentiles during this window. To formally assess the INR changes, we estimated the increase in mean INR by comparing the latest INR result in the before window to the first INR result within weeks 3-6 after statin initiation (if any) by using a paired \( t \) test. We further assessed the median effect by estimating median changes in INR levels for all statin-treated patients, as well as those treated with high- (\( \geq 40 \) mg) and low-dose (<40 mg) simvastatin in secondary analyses. Finally, we calculated the proportion of patients with an INR above the therapeutic interval (for most patients INR between 2 and 3), defined as INR > 4 and >5 by comparing the proportion of patients 1-4 weeks prior to initiating simvastatin to the proportion 3-6 weeks after.

All analyses were performed using STATA Release 14.1 (Stata- Corp, College Station, TX, USA). The study was approved by the Danish Data Protection Agency. Since data is based on anonymised register data neither approval from the Ethics Committee nor collection of informed consent was needed.

2.4 | Supplementary and sensitivity analyses

To assess the potential impact from other drugs interacting with warfarin, the main analysis was repeated excluding patients with a prescription for other potentially interacting drugs in the observation period (8 weeks before to 12 weeks after the date of statin initiation). These drugs included specific antifungals, macrolides, quinolones, metronidazole and amiodarone as described in Appendix B.\textsuperscript{11}

Furthermore, the main analysis was repeated excluding patients with a mechanical heart valve, identified through the NPR,\textsuperscript{22} to assess the potential influence of this patient group with target INR ranges other than 2-3.\textsuperscript{23}

What is already known about this subject

- Warfarin has a narrow therapeutic window and pharmacological characteristics that render the drug highly susceptible to drug-drug interactions.
- Statins and warfarin are often coprescribed due to convergent clinical indications.

What this study adds

- Initiation of statins in patients treated with warfarin is associated with a minor increase in international normalised ratio (INR), peaking at about 4 weeks after statin initiation.
- The observed association was similar for high- and low-dose simvastatin.
- The increase in INR is probably of limited clinical relevance.
Finally, some INR measurements were labelled as imprecise (up to 5-7% higher than actual values) due to prolonged storage of the blood sample before analysis of INR. We therefore conducted an analysis where these INR measurements were discarded.

2.5 | Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY.

3 | RESULTS

For the analyses, we included 1363, 165 and 23 warfarin users who had been exposed to simvastatin, atorvastatin and rosuvastatin, respectively, between 2000 and 2015.

For patients treated with simvastatin, atorvastatin and rosuvastatin, the median ages were 72 years (interquartile range [IQR] 64-79 years), 70 years (IQR 63-76) and 74 years (IQR 64-80), while the proportion of males were 58%, 62% and 47%, respectively.

INR values increased slightly after initiation of simvastatin treatment with a peak after about 4 weeks (Figure 1). Initiation of simvastatin was associated with an increase in mean INR from 2.40 to 2.71, corresponding to an increase of 0.32 (95%CI 0.25-0.38, \( P < 0.001 \)) while the median INR change was 0.2 (IQR −0.3-0.8) (Figure 2). During a time window of 1-4 weeks before initiation of statin treatment, 3.4% of patients had at least one INR measurement above 4. This proportion increased to 9.0% during 3-6 weeks after initiation of statin treatment (\( P < 0.01 \)). Similarly, the proportion of patients with INR > 5 increased from 1.3% before initiation of statin treatment to 3.2% after (\( P < 0.01 \)).

When stratifying by simvastatin dosage, we found that initiation of both high-dose (≥40 mg) simvastatin (0.33, 95%CI 0.25-0.42) and low-dose (<40 mg) simvastatin (0.29, 95%CI 0.20-0.38) was associated with a similar modest increase in mean INR. The median change in INR was 0.2 (IQR −0.3-0.9) and 0.3 (IQR −0.2-0.8) for patients receiving high and low simvastatin dose, respectively (Figure 2).

Considering atorvastatin, initiation of treatment was associated with an increase in mean INR from 2.42 to 2.69 (change 0.27, 95%CI 0.12-0.42, \( P < 0.01 \)), while for rosuvastatin it was associated with a corresponding increase from 2.31 to 2.61 (change 0.30, 95%CI −0.09-0.69, \( P = 0.121 \)). Analyses of high dose vs low dose were prohibited by low statistical power for both atorvastatin and rosuvastatin.

Sensitivity analyses excluding patients filling prescriptions for other potentially interacting drugs (n = 77), patients with a mechanical heart valve (n = 110), and INR measurements labelled as potentially imprecise (n = 81 patients with no alternative measurements) yielded virtually unchanged estimates (data not shown).

4 | DISCUSSION

In this register-based study based on a primary healthcare population, we found that initiation of simvastatin was associated with a minor, but statistically significant, increase in INR of 0.32 (95%CI 0.25-0.38, \( P < 0.001 \)), peaking approximately 4 weeks after initiation. We observed a similar response in patients initiating treatment with atorvastatin and rosuvastatin, although it failed to reach statistical significance. Sufficient data to allow analyses was not available for other statins.

The main strength of this study is the use of data obtained from daily routine work in primary health care with limited risk of selection bias. One limitation of the study is the assessment of drug use by
prescription data alone. The level of adherence to statin therapy cannot be determined and neither can the precise date of initiation of statin treatment. Early discontinuation of statins due to side effects could minimise the effect on the change in INR.\textsuperscript{24} Also, we had no available information about other factors that might impact the INR level, eg lifestyle factors and herbal medications as well as relevant diagnoses diagnosed solely in primary health care, but due to the within-person comparison most of these factors can reasonably be assumed to be constant. Furthermore, we do not report clinical outcomes. However, increases in INR are well known to increase the risk of severe bleeding.\textsuperscript{1,25,26} This is supported by a study that found initiation of statins to increase the risk of gastrointestinal bleeding in chronic warfarin users.\textsuperscript{27} In our study the proportion of patients with INR > 5 increased from 1.3 to 3.2\% after statin treatment was initiated. Importantly, however, when scrutinising the INR changes at the level of the individual, this increase reflected a small overall increase and not a pronounced increase in a subset of patients.

Finally, our study was limited to simvastatin, atorvastatin and rosvuastatin. Limited use of other statins and other cholesterol lowering therapy, eg the cholesterol absorption inhibitor ezetimibe, were not included in the present study. One study reported a possible drug interaction between warfarin and ezetimibe, which was enhanced in patients taking both ezetimibe and statins with an increase in INR (0.06 ± 0.36 for ezetimibe and 0.34 ± 0.54 for ezetimibe and statins, \( P = 0.03 \)).\textsuperscript{28}

Our findings from primary health care in the Copenhagen area support the recent findings from specialised anticoagulation clinics in Sweden presented by Andersson et al, which found an increase in INR from 2.43 to 2.58 in 5637 patients on warfarin treatment initiating simvastatin, also peaking about 4 weeks after simvastatin initiation.\textsuperscript{11} A more pronounced increase in INR was found in a small study in which INR increased from 2.5 at baseline to 3.2 after simvastatin initiation in 29 patients in stable warfarin treatment.\textsuperscript{8}

Despite relying on different CYP enzymes and transporters, we found a similar increase in INR values with use of simvastatin, atorvastatin and rosvuastatin. This suggests that non-CYP effects might play a role in this drug-drug interaction. Also, the latency in the INR increase, peaking after 4 weeks of concomitant treatment, is surprising. Of note, a similar course was seen in the study by Andersson et al.\textsuperscript{11} This does not correspond to statins directly inhibiting the CYP enzymes responsible for the metabolism of warfarin, as this would lead to a faster onset of the INR increase, eg, as seen for azole antifungals.\textsuperscript{29} To our knowledge, no alternative mechanisms have been proposed. As such, additional work identifying the mechanism through which statin use potentiates the effect of warfarin is warranted.

In conclusion, initiation of simvastatin, atorvastatin and rosvuastatin led to a minor increase in INR in patients treated with warfarin, peaking about 4 weeks after statin initiation. The magnitude of the change in INR is for most patients likely to be of limited clinical relevance. Individual risk stratification including age, use of medication and other diseases should be applied when deciding if increased INR monitoring should be performed during the initiation of statin treatment.

ACKNOWLEDGEMENTS
The authors acknowledge Martin T. Ernst for help with data management and Maja Hellfritszch for valuable input to the presentation of the findings.

COMPETING INTERESTS
F.P. reports having received a research grant from AstraZeneca, Novo Nordisk and Novartis and lecture fees from MSD, AstraZeneca, Novo Nordisk, Novartis, Eli Lilly and Boehringer Ingelheim, and has served as a consultant for AstraZeneca, Novo Nordisk, Amgen and MSD. A.P. reports participation in research projects funded by Alcon, Almirall, Astellas, Astra-Zeneca, Boehringer-Ingehelm, Novo Nordisk, Servier and LEO Pharma, all with funds paid to the institution where he was employed (no personal fees) and with no relation to the work reported in this paper.

CONTRIBUTORS
A.E. was the principal author and investigator. A.P. carried out data collection and data analysis. A.P. supervised the work. A.E. prepared the first draft manuscript. All authors read and approved the final manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Anna E. Engell https://orcid.org/0000-0003-4123-0753
Andreas L.O. Svendsen https://orcid.org/0000-0001-8050-6447
Anton Pottegård https://orcid.org/0000-0001-9314-5679

REFERENCES


APPENDIX A: THE INTERNATIONAL NORMALISED RATIO ASSAY

Coagulation, tissue factor-induced; rel.time(actual/norm; INR; IRP 67/40; proc.) was determined in sodium-citrate-stabilised plasma by Stago Prothrombin-complex assay (Diagnostica Stago, Asnières, France) on Thrombolyzer (Behnk Elektronik, Norderstedt, Germany) and on STA-R (Diagnostica Stago). For the Thrombolyzer assay the interserial coefficient of variation percentage (CV%) was 2.4% (at INR level 1.0) and 2.9% (at INR level 2.3). For the STAR assay the interserial CV% was 2.1% (at level INR 1.00) and 2.1% (at INR level 2.2). The results from the two platforms were comparable as documented by parallel analysis of 90 human plasma samples during a period of 6 days in December 2001 to May 2002. The equation from the parallel analysis was STAR = 1.0186 × Thrombolyzer –0.0305. The STA-R platform was used after 8 December 2003. The INR assay was subject to external quality control through participation in the Danish quality assessment service (DEKS, Glostrup, Denmark). The assessment schemes included five distributions annually. Each distribution comprised four samples. The results from DEKS confirmed the reliability of the assays, and the results from ELCR (from 2002 to 2015) deviated less than 5% from the method mean in 89% of the results (n = 231). The mean deviation from the method mean was –1.8% (n = 196).
# APPENDIX B: CODES AND DEFINITIONS

## Study drugs

<table>
<thead>
<tr>
<th>Drug</th>
<th>ATC</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Warfarin</td>
<td>ATC</td>
<td>B01AA03</td>
</tr>
<tr>
<td>Statins</td>
<td>ATC</td>
<td>C10AA</td>
</tr>
<tr>
<td>Simvastatin</td>
<td>ATC</td>
<td>C10AA01</td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td>ATC</td>
<td>C10AA07</td>
</tr>
<tr>
<td>Atorvastain</td>
<td>ATC</td>
<td>C10AA05</td>
</tr>
</tbody>
</table>

## Other drug use

<table>
<thead>
<tr>
<th>Drug</th>
<th>ATC</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amiodarone</td>
<td>ATC</td>
<td>C01BD01</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>ATC</td>
<td>J02AC01</td>
</tr>
<tr>
<td>Miconazole</td>
<td>ATC</td>
<td>D01AC02</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>ATC</td>
<td>J01FA01</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>ATC</td>
<td>J01MA02</td>
</tr>
<tr>
<td>Metronidazol</td>
<td>ATC</td>
<td>D06BX01</td>
</tr>
</tbody>
</table>

## Factors affecting therapeutic interval of INR

<table>
<thead>
<tr>
<th>Factor</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presence of prosthetic heart valve</td>
<td>ICD-10</td>
</tr>
</tbody>
</table>

*International Classification of Diseases Tenth Revision (ICD-10), ATC: Anatomical Therapeutic Chemical Classification System.*